Neuro-SysMed seminar – Parkinson's Disease
Welcome to the Neuro-SysMed monthly seminar series! This time topic will be on Parkinson's Disease, titled "NAD replenishment therapy in Parkinson’s disease: A New Hope?" Join us June 22nd at the auditorium in Bikuben at 11:30 - 13:00 (lunch from 11:30 - 12:00).
Main content
Speaker: Charalampos Tzoulis
Title: NAD replenishment therapy in Parkinson’s disease: A New Hope?
Place: The auditorium in Bikuben, Jonas Lies vei 69 (campus Haukeland University Hospital)
Time: Wednesday June 22, 2022 at 11:30 - 13:00 (lunch from 11:30 - 12:00).
Register here: https://skjemaker.app.uib.no/view.php?id=12900005
Deadline for registration: June 17, 2022.
Abstract: Parkinson’s disease (PD) is a major cause of death and disability, with a rapidly growing global socioeconomic impact. The etiopathogenesis of PD remains largely unknown and current treatments are purely symptomatic, making no impact on disease progression. Despite several candidate neuroprotective therapies showing encouraging preclinical results, these have consistently failed to show disease-modifying effects in clinical trials. A growing body of evidence suggests that mitochondrial dysfunction and aberrant NAD-metabolism play an important role in PD, and that therapies targeting these pathways may confer neuroprotective effects. This presentation will cover historical aspects and hallmark experimental evidence supporting these hypotheses. Furthermore, I will illustrate how basic laboratory research has led to the first clinical trial of NAD replenishment therapy in PD, which has shown highly encouraging results.
Short bio: Charalampos Tzoulis, is Professor of Neurology and Neurogenetics at the University of Bergen and Haukeland University Hospital, Bergen Norway. As a clinical neurologist, Prof. Tzoulis is an expert on movement disorders and neurodegeneration, including dementia and parkinsonism. His research focuses on exploring the role of mitochondrial dysfunction in Parkinson’s disease (PD), with the aim to improve patient diagnosis and develop neuroprotective therapies. Currently, he is the Head of the Neuromics Research Group, co-Director of the Neuro-SysMed Center of Excellence for Clinical Research in Neurological diseases, where he leads the research on PP, and Director of the K.G Jebsen Center for Translational Research in Parkinson’s disease.
Neuromics research group: https://neuromics.org/
Neuro-SysMed Center: https://neuro-sysmed.no/
ORCID: 0000-0003-0341-5191